Chorzalska et al. have reported that low expression of Abi1 in CD34+ cells from CML patients and K562 CML cell line is linked to drug resistance and is associated with elevated activation of ERK and Akt, the pathways that are activated by Bcr-Abl and are important for Bcr-Abl-induced cell growth and leukemia development [32]. This evidence concerns the gene ABI1 and chronic myelogenous leukemia, BCR-ABL1 positive.